Call Us: (1) 608 441-2729 - Email Us email@example.com
M2SR: The Vaccine
Board of Directors
Clinical Advisory Board
News and opinions
Isthmus Article: A Better Flu Vaccine. FluGen strives to make it more effective, plus pain-free
November 6, 2012
Share this Story
Comments are closed.
M2sr Vaccine Technology: How Flugen Is Introducing New Solutions and Strategies for Influenza and COVID-19 Protection
Dual defense: FluGen’s M2SR vaccine shields against influenza and COVID-19
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
FluGen Announces First Subject Dosed in Phase 1b Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults
FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference
(c)2016 FluGen, Inc. All rights reserved.
Back to Top